Solution reagent kit AVENIO V2

for researchtissueNGS

The AVENIO Tumor Tissue CGP Kit is an in-house next-generation sequencing (NGS) research assay that provides comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. Designed to match the content of the 324 gene FoundationOne® CDx panel, the kit leverages the proven technology of Foundation Medicine and Roche’s expertise to help your lab obtain reliable genomic insights. Leverage the power of Roche and Foundation Medicine® Experts in personalized medicine and comprehensive genomic profiling: 800+ peer reviewed publications, 1.3 million+ clinical samples reported. Unlock high-quality meaningful genomic insights Analyzes 335 relevant genes, four classes of genomic alterations, and complex genomic signatures including TMB, MSI, gLOH and the newly added HRDsig. Utilize fast and convenient NGS workflows One workflow from DNA extraction to data analysis. Fast 2-day library prep and short 1-hour ligation with a total 5-day turnaround time from DNA extraction to result generation. FoundationOne® Analysis Platform + AVENIO Connect Software The FoundationOne® Analysis Platform processes the AVENIO Tumor Tissue CGP Kit V2 sequencing data from the Illumina NextSeq500/500/550Dx (Research Use Only mode) instruments,* and produces files with filtered variant calls and QC metrics which are made available to the user through AVENIO Connect Software. Leveraging the Foundation Medicine knowledgebase with 1.3 million+ genomic profiles,4 this post-sequencing analysis software makes it easy for customers to analyze samples and access the information they need. Robust analytical variant detection performance across genomic alterations